Combining Varenicline and Guanfacine for Smoking Cessation

NCT04198116 ↗

Phase 2 Completed 167 enrolled Yale University National Institute on Drug Abuse (NIDA) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The novel design of this study combines a laboratory paradigm to evaluate stress-induced smoking behavior and smoking-related reinforcement, followed by a 12-week treatment phase to evaluate clinical outcomes.

Timeline

Start: 2020-11-01
Primary completion: 2025-04-30
Completion: 2025-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Guanfacine	Small molecule	6 mg	Oral
Subject	Varenicline	Small molecule	2 mg	Oral

Indications

No indication recorded.